Library Item - Page 16 of 792 Posts on Medivizor

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

Posted by Medivizor on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of allogeneic hematopoietic cell transplant (alloHCT) for older patients with acute myeloid leukemia (AML) using treosulfan (Trecondi) compared to reduced intensity busulfan (Myleran) conditioning. This study concluded that treosulfan conditioning appears to be more suitable for...

How effective and safe is rituximab biosimilar HLX01 in patients with moderate to severe rheumatoid arthritis?

Posted by Medivizor on Dec 31, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rituximab (Rituxan) biosimilar HLX01 combined with methotrexate (MTX; Trexall) in patients with moderate to severe rheumatoid arthritis (RA) following inadequate responses to MTX. The study showed that HLX01 added to MTX resulted in improvements compared to placebo in these...

How beneficial is the addition of metformin to insulin therapy for adolescents with type 1 diabetes?

Posted by Medivizor on Dec 31, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effectiveness and safety of adding metformin (Glucophage) to insulin therapy in the treatment of adolescents with type 1 diabetes (T1D). The study showed that the use of metformin in these patients resulted in improved blood glucose control and body mass index (BMI) with an increased risk of...

Is the use of sodium-glucose cotransporter 2 inhibitors related to the occurrence of eye diseases in patients with type 2 diabetes?

Posted by Medivizor on Dec 31, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the link between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and eye (ocular) diseases in patients with type 2 diabetes (T2D). The data showed that there was no link between the occurrence of eye diseases and SGLT2is in these patients. Some SGLT2is such as ertugliflozin (Steglatro) and empagliflozin...

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Posted by Medivizor on Dec 31, 2022 in Melanoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of encorafenib (Braftovi) alone or in combination with binimetinib (Mektovi) or vemurafenib (Zelboraf) alone in patients with BRAF-mutated advanced melanoma. The data showed that the encorafenib plus binimetinib combination lead to long-term effectiveness and no new safety...

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Posted by Medivizor on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus...

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Posted by Medivizor on Dec 31, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus...

Evaluating the effectiveness and safety of adding oxaliplatin (3 months vs 6 months) to 6 months of fluoropyrimidine after surgery in patients with stage II or III colon cancer.

Posted by Medivizor on Dec 31, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding oxaliplatin (Eloxatin; 3 months vs 6 months) to 6 months of fluoropyrimidine therapy such as 5-Fluorouracil (Adrucil) or capecitabine (Xeloda) as adjuvant (treatment after surgery) treatment in patients with stage II or III colon cancer. The data showed that adding 3 months of...

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Posted by Medivizor on Dec 31, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of anlotinib (AL3818) as a third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that anlotinib as a third-line treatment was effective with manageable side effects in these patients. Some background NSCLC is the most common form of lung...

Evaluating the long-term effectiveness and safety of bosutinib versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia.

Posted by Medivizor on Dec 30, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of bosutinib (Bosulif) versus imatinib (Gleevec) in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML). The data showed that bosutinib had better effectiveness than imatinib in these patients. Some background CML is a type of cancer that starts...

Comparing the effectiveness and safety between biodegradable and durable polymer drug-eluting stents in patients with acute coronary syndrome.

Posted by Medivizor on Dec 30, 2022 in Coronary artery disease | 0 comments

In a nutshell This study compared the effectiveness and safety between biodegradable polymer (BP) drug-eluting stents (DES) and durable polymer (DP) DESs in patients with acute coronary syndrome (ACS). The data showed that both stent types demonstrated excellent effectiveness and safety after 1 year. The authors suggested that BP-DES may be more...

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Posted by Medivizor on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of fulvestrant (Faslodex) plus capivasertib (AZD5363) in patients with aromatase inhibitor-resistant estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that fulvestrant plus capivasertib significantly improved the survival outcomes in these...

Library Item Posts on Medivizor

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

How effective and safe is rituximab biosimilar HLX01 in patients with moderate to severe rheumatoid arthritis?

How beneficial is the addition of metformin to insulin therapy for adolescents with type 1 diabetes?

Is the use of sodium-glucose cotransporter 2 inhibitors related to the occurrence of eye diseases in patients with type 2 diabetes?

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Evaluating the effectiveness and safety of adding oxaliplatin (3 months vs 6 months) to 6 months of fluoropyrimidine after surgery in patients with stage II or III colon cancer.

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Evaluating the long-term effectiveness and safety of bosutinib versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia.

Comparing the effectiveness and safety between biodegradable and durable polymer drug-eluting stents in patients with acute coronary syndrome.

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Categories

Recent Posts

Archives

Library Item Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email